AbbVie Ownership
ABBV Stock | USD 166.41 1.75 1.06% |
Shares in Circulation | First Issued 2011-03-31 | Previous Quarter 1.8 B | Current Value 1.8 B | Avarage Shares Outstanding 1.6 B | Quarterly Volatility 94.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
AbbVie |
AbbVie Stock Ownership Analysis
About 72.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.45. AbbVie Inc last dividend was issued on the 12th of April 2024. AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Abbvie operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 50000 people. For more info on AbbVie Inc please contact Richard Gonzalez at 847 932 7900 or go to https://www.abbvie.com.Besides selling stocks to institutional investors, AbbVie also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different AbbVie's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align AbbVie's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
AbbVie Quarterly Liabilities And Stockholders Equity |
|
AbbVie Insider Trades History
Less than 1% of AbbVie Inc are currently held by insiders. Unlike AbbVie's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against AbbVie's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of AbbVie's insider trades
AbbVie Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AbbVie is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AbbVie Inc backward and forwards among themselves. AbbVie's institutional investor refers to the entity that pools money to purchase AbbVie's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Northern Trust Corp | 2023-12-31 | 20.9 M | Norges Bank | 2023-12-31 | 20.8 M | Bank Of America Corp | 2023-12-31 | 18.6 M | Legal & General Group Plc | 2023-12-31 | 15.2 M | Ameriprise Financial Inc | 2023-12-31 | 14.2 M | Fmr Inc | 2023-12-31 | 11.1 M | Ubs Group Ag | 2023-12-31 | 10.9 M | Hhg Plc | 2023-12-31 | 9.7 M | T. Rowe Price Associates, Inc. | 2023-12-31 | 9.5 M | Vanguard Group Inc | 2023-12-31 | 160.4 M | Blackrock Inc | 2023-12-31 | 143.2 M |
AbbVie Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AbbVie insiders, such as employees or executives, is commonly permitted as long as it does not rely on AbbVie's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AbbVie insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Edward Rapp over two weeks ago Acquisition by Edward Rapp of 212 shares of AbbVie at 182.1 subject to Rule 16b-3 | ||
Carrie Strom over six months ago Payment of 2876 shares by Carrie Strom of AbbVie subject to Rule 16b-3 |
AbbVie Outstanding Bonds
AbbVie issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AbbVie Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AbbVie bonds can be classified according to their maturity, which is the date when AbbVie Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
ABBVIE INC Corp BondUS00287YBZ16 | View | |
ABBVIE INC Corp BondUS00287YBX67 | View | |
ABBVIE INC Corp BondUS00287YBV02 | View | |
ABBVIE INC Corp BondUS00287YCB39 | View | |
ABBVIE INC Corp BondUS00287YCA55 | View | |
ABBVIE INC 445 Corp BondUS00287YAW93 | View | |
ABBVIE INC 43 Corp BondUS00287YAV11 | View | |
ABBVIE INC 32 Corp BondUS00287YAY59 | View |
AbbVie Corporate Filings
8K | 3rd of April 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
2nd of April 2024 Other Reports | ViewVerify | |
F4 | 22nd of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
18th of March 2024 Other Reports | ViewVerify |
Pair Trading with AbbVie
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AbbVie position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AbbVie will appreciate offsetting losses from the drop in the long position's value.Moving together with AbbVie Stock
0.85 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
Moving against AbbVie Stock
0.45 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to AbbVie could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AbbVie when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AbbVie - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AbbVie Inc to buy it.
The correlation of AbbVie is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AbbVie moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AbbVie Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AbbVie can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the AbbVie Inc information on this page should be used as a complementary analysis to other AbbVie's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for AbbVie Stock analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Transaction History View history of all your transactions and understand their impact on performance | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is AbbVie's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AbbVie. If investors know AbbVie will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AbbVie listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.67) | Dividend Share 5.99 | Earnings Share 2.71 | Revenue Per Share 30.723 | Quarterly Revenue Growth (0.05) |
The market value of AbbVie Inc is measured differently than its book value, which is the value of AbbVie that is recorded on the company's balance sheet. Investors also form their own opinion of AbbVie's value that differs from its market value or its book value, called intrinsic value, which is AbbVie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AbbVie's market value can be influenced by many factors that don't directly affect AbbVie's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AbbVie's value and its price as these two are different measures arrived at by different means. Investors typically determine if AbbVie is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AbbVie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.